$131MGrowth, 7 August 2025
Funds China launch of topical JAK inhibitor and late-stage oncology programs
- Amount
- $131M
- Stage
- Growth
- Announced
- 7 August 2025
- Lead
- OrbiMed
- Other investors
- Qiming Venture Partners, TF Capital, BioTrack Capital, 5Y Capital
- Use of funds
- Funds China launch of topical JAK inhibitor and late-stage oncology programs
- Checked
- Announced by the company
- Sources
- Minghui Pharmaceutical raises USD 131M Pre-IPO plataformamedia.com
Minghui Pharmaceutical raises USD 131M Pre-IPO techstartups.com